Opinion|Videos|April 7, 2025
Clinical Considerations for Choosing a Systemic Agent for Patients With Atopic Dermatitis
Panelists discuss how standard first-line treatments for nonresponsive patients often include systemic therapies like corticosteroids or immunomodulators. Second-line options may involve biologics or advanced systemic agents. Patient input is crucial in tailoring treatments to preferences, needs, and risks.
Advertisement
Episodes in this series
Video content above in prompted by the following:
- Do you have standard first-line and second-line treatment recommendations for patients that are nonresponsive to topical treatments? How important is patient input in choosing a treatment method?
Advertisement
Related to this article
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.
The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.
Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.
As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.
Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.
Andrea Murina, MD, weighs whether she would recommend medicine to her own children amid AI, physician burnout, and evolving residency training standards.
Advertisement
Advertisement
Trending on HCPLive
1
The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH
2
FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome
3
Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older
4
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
5